Clinical trials: Pulmonary Resistance
Early Adult Lung Function, Small Airway Disease
Factors Affecting Early Adult Lung Function
Attainment of peak healthy lung function during the 18-26 yr window is a strong determinant of the rate of lung function decline during the later years of life.
- Conditions
- Early Adult Lung Function, Small Airway Disease, Metabolic Syndrome
- Trial name
- FEAL (NCT03187158)
- Testing
- Forced Oscillation Technique
- Where
- India
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Council of Scientific and Industrial Research, India
Renal Cell Carcinoma, Lung Carcinoma
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment).
- Conditions
- Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
- Trial name
- NCT00026663
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Congenital Disorders
Pulmonary Resistance in Fontan Who Have Undergone Heart Transplantation
Clinical evidence reveals that some patients who undergo cardiac transplantation exhibit problems with pulmonary vascular resistance as well.
- Trial name
- NCT00268047
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Children's Healthcare of Atlanta
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Pneumonia, Ventilator-Associated
Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia
The TOP-MDRVAP trial will test whether inhaled tobramycin can safely prevent pneumonia caused by multidrug-resistant bacteria in adults who need a breathing machine. Tobramycin is an antibiotic.
- Trial name
- TOP-MDRVAP (NCT07856355)
- Testing
- Tobramycin inhalation solution
- Where
- China
- Volunteers
- 574 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Bacterial Infection
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
This study will enroll 460 subjects who have new pulmonary infiltrates during their ICU stay and who are at low risk of having pneumonia, as determined using the Clinical Pulmonary Infection Score (CPIS).
- Trial name
- NCT00307099
- Testing
- Meropenem, Standard antibiotic therapy
- Where
- 10 sites in United States
- Volunteers
- 460 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have…
- Trial name
- ORIGIN2 (NCT07158489)
- Testing
- Gemcitabine + Ivonescimab
- Where
- 8 sites in Switzerland
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Malaria, Malaria in Pregnancy
ERASE - Impact of COVID-19 on Malaria Control
Objective: Measure incidence of malaria and malaria-related outcomes, evaluating potential impact of the SARS-CoV2 epidemic and of antimalarial resistance in Oyam and Kole district, Uganda with focus on pregnant women.
- Trial name
- ERASE (NCT05348746)
- Testing
- Advanced Analysis of Polymorphism
- Volunteers
- 300 people
- Sponsor
- Doctors with Africa - CUAMM
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Metastatic Non Small Cell Lung Cancer
C-TIL051 in Non-Small Cell Lung Cancer
The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1.
- Trial name
- NCT05676749
- Testing
- C-TIL051
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbelZeta Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung…
- Trial name
- Chime (NCT01900652)
- Testing
- Emibetuzumab, Erlotinib
- Where
- 59 sites in United States, Belgium and 8 more
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Asthma
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance.
- Trial name
- NCT06224634
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
Smoking
Effect of Lower Limb Resistance Versus Endurance Training in Smokers
Patients was selected based on inclusion and exclusion criteria. Experimental group was treated with Resistance training while control group received endurance training.
- Trial name
- NCT06674174
- Testing
- lower limb strength training, endurance training
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Chronic Obstructive Pulmonary Disease
Acute Effects of a Flutter Device in COPD
Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible, and is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles…
- Trial name
- AEFLUC (NCT01832961)
- Testing
- Flutter valve exercises, Flutter and bronchodilator exercises
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Lung Cancer
Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer
This single-centre prospective study is aimed at analysing, by means of liquid biopsy with next generation sequencing analysis on circulating tumor DNA, resistance mutations arising during therapy with selective inhibitors in…
- Trial name
- MUT-ONC (NCT06081270)
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Milano Bicocca
Tuberculosis, Multi-Drug Resistant Tuberculosis
Metronidazole for Pulmonary Tuberculosis (South Korea)
This study will evaluate the effect of adding metronidazole to standard second-line therapy for tuberculosis in patients who have multi-drug resistant tuberculosis (MDR-TB) of the lungs.
- Trial name
- NCT00425113
- Testing
- Metronidazole, Blood Draw, CT Scan
- Where
- 2 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Ventilator-Associated, Pneumonia
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
Secondary infections remain a major cause of mortality in critically ill patients, mainly because of high prevalence of multidrug-resistant microorganisms.
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bloodstream Infection, Sepsis
- Trial name
- NCT04839653
- Testing
- Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h, Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h, Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- MEDSI Clinical Hospital 1, ICU